



SPECIAL ARTICLE

Resistance to β -lactams in enterococci



Paula Gagetti^{a,b,*}, Laura Bonofiglio^{a,c}, Gabriela García Gabarrot^{a,d},
Sara Kaufman^{a,e}, Marta Mollerach^{a,b}, Laura Vigliarolo^{a,f}, Martha von Specht^{a,g,h},
Inés Toresani^{a,i}, Horacio A. Lopardo^{a,f}

^a Grupo STREP de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología, Argentina

^b Servicio Antimicrobianos, Departamento de Bacteriología, Instituto Nacional de Enfermedades Infecciosas (INEI), ANLIS "Dr Carlos G. Malbrán", Ciudad Autónoma de Buenos Aires, Argentina

^c Cátedra de Microbiología, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

^d Programa de Desarrollo de las Ciencias Básicas (PEDECIBA), Universidad de la República, Montevideo, Uruguay

^e Sección Microbiología Clínica, División Laboratorio, Hospital Juan A. Fernández, Ciudad Autónoma de Buenos Aires, Argentina

^f Cátedra de Microbiología Clínica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina

^g Laboratorio de Bacteriología, Hospital "Dr Fernando Barreyro", Posadas, Misiones, Argentina

^h Departamento de Microbiología, Facultad de Ciencias Exactas, Químicas y Naturales, Universidad Nacional de Misiones, Posadas, Provincia de Misiones, Argentina

ⁱ Cátedra de Bacteriología, Facultad de Ciencias Bioquímicas, Universidad Nacional de Rosario, Rosario, Provincia de Santa Fe, Argentina

Received 7 September 2017; accepted 23 January 2018

Available online 20 September 2018

KEYWORDS

Enterococci;
Enterococcus faecalis;
Enterococcus faecium;
 β -Lactams;
Antimicrobial resistance

Abstract Enterococci are intrinsically resistant to several antimicrobial classes and show a great ability to acquire new mechanisms of resistance. Resistance to β -lactam antibiotics is a major concern because these drugs either alone or in combination are commonly used for the treatment of enterococcal infections. Ampicillin resistance, which is rare in *Enterococcus faecalis*, occurs in most of the hospital-associated *Enterococcus faecium* isolates. High-level resistance to ampicillin in *E. faecium* is mainly due to the enhanced production of PBP5 and/or by polymorphisms in the beta subunit of this protein. The dissemination of high-level ampicillin resistance can be the result of both clonal spread of strains with mutated *pbp5* genes and horizontal gene transfer.

© 2018 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: pgagetti@anlis.gov.ar (P. Gagetti).

PALABRAS CLAVE

Enterococos;
Enterococcus
faecalis;
Enterococcus
faecium;
 β-Lactámicos;
 Resistencia

Resistencia a los β-lactámicos en enterococos

Resumen Los enterococos son intrínsecamente resistentes a varias clases de antimicrobianos y presentan una gran capacidad para adquirir mecanismos de resistencia. La resistencia a los antibióticos β-lactámicos es preocupante porque estos fármacos solos o combinados se usan comúnmente para el tratamiento de las infecciones enterocócicas. La mayoría de los aislamientos hospitalarios de *Enterococcus faecium* presentan resistencia a la ampicilina, la cual es rara en *Enterococcus faecalis*. El alto nivel de resistencia a la ampicilina en *E. faecium* se debe principalmente a la hiperproducción de PBP5 y/o a polimorfismos en la subunidad beta de esta proteína. La propagación de esta resistencia puede deberse tanto a la diseminación clonal de cepas con genes *pbp5* mutados como a la transferencia horizontal de genes.

© 2018 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Enterococci are major nosocomial pathogens due to their intrinsic resistance to many antimicrobials as well as to their ability to acquire new mechanisms of resistance. Among enterococcal species, *Enterococcus faecalis* and *Enterococcus faecium* are the most frequently encountered²².

All enterococci exhibit decreased susceptibility to penicillin and ampicillin, as well as high-level resistance to most cephalosporins and all semi-synthetic penicillins, as the result of expression of low-affinity penicillin-binding proteins¹⁶.

For many strains, their level of resistance to ampicillin does not preclude the clinical use of this agent. In fact, ampicillin remains the treatment of choice for enterococcal infections.

Healthcare-associated enterococcal infections caused by *E. faecium* have been increasing significantly over the last decades. This increase began with the emergence of high-level ampicillin resistance followed by the addition of vancomycin resistance; these resistances are very uncommon (and have not been reported together) in *E. faecalis*.

The aim of the present review is to describe the mechanisms and the prevalence of β-lactam resistance in *E. faecalis* and *E. faecium*, since in other species of enterococci such as *E. casseliflavus*, *E. gallinarum*, *E. raffinosus*, *E. avium*, *E. caccae*, *E. dispar*, *E. durans*, *E. hirae*, and others, also of clinical interest in humans although of less frequent presentation, high-level resistance to penicillin and aminopenicillins have not yet been described.

Intrinsic low-level β-lactam resistance

Antibiotics in the β-lactam family inhibit bacterial growth by serving as suicide substrates for the D,D-transpeptidases (also known as penicillin-binding proteins, or PBPs) that catalyze the cross-linking of peptidoglycan peptide side chains during the synthesis of mature peptidoglycan. Once modified by a β-lactam antibiotic, PBPs are inactivated, thereby preventing continued cell wall synthesis³⁰.

Enterococci express a low-affinity PBP5 (PBP5 in *E. faecium*, and in *E. faecalis* sometimes denominated PBP4)

that bind weakly to β-lactam antibiotics. Even strains isolated from primitive populations in the Solomon Islands (who had had little or no exposure to manufactured antibiotics) as well as strains isolated early in the antibiotic era display this property²². In general enterococci are approximately 100-fold less susceptible to β-lactams than streptococci³⁰. This trait is encoded by chromosomal determinants in the core genome of these organisms and involves the production of the low-affinity class B penicillin-binding protein 5 (PBP5). Due to its relatively low affinity for β-lactams, PBP5 is capable of carrying out peptidoglycan synthesis at concentrations of β-lactam antibiotics that saturate all the transpeptidase domain of other enterococcal PBPs¹⁶.

The level of intrinsic resistance differs among the β-lactam antimicrobials. Generally, penicillins (e.g. ampicillin) have the highest activity, carbapenems slightly lower and cephalosporins have the lowest activity²².

Acquired high-level resistance

High-level resistance to ampicillin emerged in hospitals in the United States during the 1970s and the 1980s².

Ampicillin resistance, is rare in *E. faecalis*, but occurs in ~90% of modern-day hospital-associated *E. faecium* isolates^{2,4}. In Argentina, according to Latin American Surveillance of Antimicrobial Resistance (ReLAVRA) data from 2015, ampicillin resistance rate is 1.8% in *E. faecalis* and 85% in *E. faecium*²⁷.

High-level resistance to ampicillin in *E. faecium* (MIC ≥ 128 mg/l) was initially explained by either the enhanced production of PBP5, and/or by polymorphisms in the beta subunit of this protein⁸. Further analysis of *E. faecium* strains with different levels of ampicillin susceptibility revealed that the variability of PBP5 sequences is mostly due to changes in 21 specific positions of the protein, suggesting that a sequential acquisition of mutations could have contributed to the progressive resistance to ampicillin from the early 1980s^{9,25}.

Another β-lactam resistance mechanism that does not involve PBPs has been detected in an ampicillin resistant laboratory mutant strain of *E. faecium* (MIC > 2000 mg/l). A bypass of the reaction of D,D-transpeptidation that occurs

during the final steps of the peptidoglycan synthesis was detected by removal of the PBP5 gene¹⁹. Mutations in genes encoding other species-specific proteins that participate in the cell wall synthesis, may also slightly increase the MIC values even in the absence of PBP5²⁸.

The first isolates of β -lactamase-producing *E. faecalis* were identified in Texas in 1981²². Although rare, these isolates have been spread from seven states of the USA²³, and also were described in Lebanon, Canada, and Argentina, where 6 strains were isolated at the Hospital Garrahan²⁴. This mechanism of resistance is more common in *E. faecalis* than in *E. faecium*. However, β -lactamase producer *E. faecium* strains were reported, only one isolate in Richmond in 1992 and 8 epidemiologically unrelated isolates in Modena in 2010²⁹.

Plasmid-mediated *bla* genes (encoding β -lactamases) were first described in *E. faecalis* in 1983¹⁵. Some strains of *Enterococcus* produce a β -lactamase identical to the staphylococcal enzyme. These strains are characterized by being resistant to penicillin, aminopenicillins (ampicillin) and ureido-penicillins (piperacillin), but susceptible to imipenem and combinations of β -lactams with β -lactamase inhibitors (such as ampicillin-sulbactam), so they no constitute a therapeutic challenge.

Enterococci produce so little β -lactamase that it cannot be detected by routine susceptibility laboratory tests, such as diffusion or dilution methods. These isolates can be detected using nitrocefin, but are so rare that its use is not recommended of routine. They can also be detected by difference in size between the inhibition zone of ampicillin and ampicillin-sulbactam, considering as positive result when difference is greater than 4 mm¹⁷.

Origin and evolution of β -lactam resistance in *E. faecium*

E. faecium population biology is dominated by two main phylogenomic groups, clade A and clade B. Most isolates resistant to ampicillin belong to clade A or "hospital-associated clade" mainly comprising *E. faecium* from hospitalized patients⁹. A subgroup within the clade A, clade A1, is enriched in mobile genetic elements and have enhanced ability to colonize and persist in human hosts due to the presence of adhesins and specific metabolic traits. In contrast, the clade B or "community-associated *E. faecium*" mostly comprises ampicillin susceptible isolates from healthy, non-hospitalized individuals¹⁴.

Polymorphisms in the PBP5 protein sequences allowed grouping of PBP5 variants in clusters that mimic the phylogenomic diversification of *E. faecium* suggested a model for evolvability of this enterococcal species consisting of a first split of "clade B" and "clade A" coincidental with human and animal co-habitation occurring 30 000 years ago, and a further split of "clade A" in subclades "A1" and "A2" after the introduction of antibiotics in the late 1940s⁹.

Interpretation of susceptibility tests

According to CLSI recommendations, the results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin. Susceptibility

to amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin, and piperacillin-tazobactam among non- β -lactamase producing enterococci may be predicted by ampicillin results. Additionally, ampicillin susceptibility can be used to predict imipenem susceptibility, providing the species is confirmed to be *E. faecalis*.

Until recently it was assumed that *E. faecalis* susceptible to ampicillin were also susceptible to penicillin, but in recent years clinical penicillin-resistant but ampicillin-susceptible *E. faecalis* isolates exhibiting an unusual phenotype were reported. Isolates with this phenotype were described in a study performed in Greece between 2003 and 2004, where 90 of 287 isolates of *E. faecalis* presented this phenotype²⁰. In a study conducted in Denmark in 2007, 20 of 33 isolates from blood of patients with bacteraemia from 7 hospitals presented this phenotype, being two of them also resistant to imipenem¹³. In another study performed in Brazil between 2006 and 2010, 34 of 317 isolates presented this phenotype associated with resistance to piperacillin⁵. A recent study showed that a point mutation in the PBP4 is responsible to this phenotype⁶.

Treatment of enterococcal infections

Uncomplicated enterococcal infections may be adequately treated with monotherapy, whereas for the treatment of severe infections such as endocarditis a synergistic regimen is needed¹⁵.

Penicillin (or ampicillin) alone or combined with an aminoglycoside was for over half a century the treatment of choice for enterococcal infections. Despite the good inhibitory *in vitro* activity of ampicillin and penicillin against most *E. faecalis*, it has been shown that β -lactam monotherapy is not suitable for treating endovascular infections. These infections usually require bactericidal therapy that, for many strains, is not achieved with the use of ampicillin or penicillin alone as a result of the tolerance of enterococci to these compounds¹.

Enterococci are tolerant to the (normally) bactericidal activity of cell-wall active agents, such as β -lactam antibiotics and vancomycin. Tolerance implies that the bacteria can be inhibited by clinically achievable concentrations of the antibiotic, but will only be killed by concentrations far in excess of the inhibitory concentration. Enterococcal tolerance can be overcome by combining cell-wall active agents with an aminoglycoside¹⁶. The synergistic effect occurs because the antibiotic that acts on the cell wall allows the aminoglycoside to reach its action site.

In a study performed in Argentina by Predari et al., 201 strains of *E. faecalis* were studied. Penicillin and ampicillin killing-curves were performed with 5 aminoglycosides in 31 selected isolates and it was determined that a synergistic combination was not always achieved even with low levels of resistance, less than 2000 mg/l at that time²⁶.

In recent years resistance to aminoglycosides increased significantly by the wide spread of genes encoding aminoglycoside modifying enzymes. In addition, the use of aminoglycosides is limited in critically ill patients because of its nephrotoxic effect. The combination of ceftriaxone (or cefotaxime) and ampicillin was recently tested as an alternative.

There are several studies that support the use of combined therapy to treat enterococcal endocarditis infections. Mainardi and colleagues demonstrated that, at low amoxicillin concentrations, the PBPs 4 and 5 would be partially saturated, but the nonessential PBPs 2 and 3 could participate in building the cell wall. The combination with cefotaxime would totally saturate PBPs 2 and 3, producing the bactericidal synergistic effect¹⁸.

A work performed in Argentina to evaluate in vitro activity of ampicillin–ceftriaxone against 30 strains of *E. faecalis* recovered from invasive infections in patients admitted to a university hospital, showed synergy in the 73.3% of the isolates³.

Thereafter, Gavaldà and colleagues showed that the combination of ampicillin plus ceftriaxone was as effective as ampicillin plus gentamicin for the treatment of experimental endocarditis due to non-high-level resistance to aminoglycosides (HLAR) *E. faecalis* and more effective than ampicillin alone in experimental endocarditis due to HLAR *E. faecalis*^{10,11}. In a multicenter study conducted by the same group in 13 Spain hospitals, from 43 patients with *E. faecalis* infective endocarditis (21 HLAR and 22 non-HLAR), the cure occurred in 71.4 and 72.7% of patients respectively, at the end of treatment, with only 2 relapses in the non-HLAR *E. faecalis* endocarditis group¹². Additionally, in 2008 a successful treatment of relapse of a patient unsuccessfully treated with ampicillin-gentamicin was demonstrated²¹. Based on these studies the American Heart Association recommended the use of ampicillin–ceftriaxone as an alternative for the treatment of *E. faecalis* infective endocarditis with HLAR.

A study performed by Fernandez Hidalgo in 2013 compared the effectiveness of ampicillin–ceftriaxone and ampicillin–gentamicin combinations for treating *E. faecalis* infective endocarditis. The study included 291 patients from 17 hospitals in Spain and 1 in Italy and demonstrated that the treatment with ampicillin-ceftriaxone was similar to treatment with ampicillin–gentamicin, with the advantage of this latter combination regarding toxicity⁷.

Conclusion

The treatment of serious infections caused by enterococci is a therapeutic challenge due to the ability they have to develop resistance to antibiotics. However, β -lactam antibiotics, alone or in combination, continue to be useful in the treatment of severe enterococcal infections.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

- Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. *Clin Microbiol Infect*. 2010;16:555–62.
- Arias CA, Murray BE. The rise of the *Enterococcus*: beyond vancomycin resistance. *Nat Rev Microbiol*. 2012;10:266–78.
- Burguer Moreira N, Nastro M, Vay C, Famiglietti A, Rodríguez CA. In vitro activity of ampicillin–ceftriaxone against *Enterococcus faecalis* isolates recovered from invasive infections. *Rev Argent Microbiol*. 2016;48:57–61.
- Cercenado E. *Enterococcus*: resistencias fenotípicas y genotípicas y epidemiología en España. *Enferm Infecc Microbiol Clin*. 2011;29:59–65.
- Conceição N, Barata de Oliveira C, da CH, Pinheiro da Silva LE, Cardoso de Souza LR, Gonçalves de Oliveira A. Ampicillin susceptibility can predict in vitro susceptibility of penicillin-resistant, ampicillin-susceptible *Enterococcus faecalis* isolates to amoxicillin but not to imipenem and piperacillin. *J Clin Microbiol*. 2012;50:3729–31.
- Conceição N, Pinheiro da Silva LE, Darini AL, Pitondo-Silva A, Gonçalves de Oliveira A. Penicillin-resistant, ampicillin-susceptible *Enterococcus faecalis* of hospital origin: *pbp4* gene polymorphism and genetic diversity. *Infect Genet Evol*. 2014;28:289–95.
- Fernández-Hidalgo N, Almirante B, Gavaldà J, Gurgui M, Peña C, de Alarcón A, Ruiz J, Vilacosta I, Montejó M, Vallejo N, López-Medrano F, Plata A, López J, Hidalgo-Tenorio C, Gálvez J, Sáez C, Lomas JM, Falcone M, de la Torre J, Martínez-Lacasa X, Pahissa A. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating *Enterococcus faecalis* infective endocarditis. *Clin Infect Dis*. 2013;56:1261–8.
- Fontana R, Aldegheri M, Ligozzi M, López H, Sucari A, Satta G. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in *Enterococcus faecium*. *Antimicrob Agents Chemother*. 1994;38:1980–3.
- Galloway-Peña JR, Rice LB, Murray BE. Analysis of PBP5 of early U.S. isolates of *Enterococcus faecium*: sequence variation alone does not explain increasing ampicillin resistance over time. *Antimicrob Agents Chemother*. 2011;55:3272–7.
- Gavaldà J, Torres C, Tenorio C, López P, Zaragoza M, Capdevila JA, Almirante B, Ruiz F, Borrell N, Gomis X, Pigrau C, Baquero F, Pahissa A. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to *Enterococcus faecalis* strains highly resistant to aminoglycosides. *Antimicrob Agents Chemother*. 1999;43:639–46.
- Gavaldà J, Onrubia PL, Gomez MT, Gomis X, Ramírez JL, Len O, Rodríguez D, Crespo M, Ruiz I, Pahissa A. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to *Enterococcus faecalis* with no high-level resistance to aminoglycosides. *J Antimicrob Chemother*. 2003;52:514–7.
- Gavaldà J, Len O, Miró JM, Muñoz P, Montejó M, Alarcón A, de la Torre-Cisneros J, Peña C, Martínez-Lacasa X, Sarria C, Bou G, Aguado JM, Navas E, Romeu J, Marco F, Torres C, Tornos P, Planes A, Falcó V, Almirante B, Pahissa A. Brief communication: treatment of *Enterococcus faecalis* endocarditis with ampicillin plus ceftriaxone. *Ann Intern Med*. 2007;146:574–9.
- Guardabassi L, Larsen J, Skov R, Schønheyder HC. Gentamicin-resistant *Enterococcus faecalis* sequence type 6 with reduced penicillin susceptibility: diagnostic and therapeutic implications. *J Clin Microbiol*. 2010;48:3820–1.
- Guzmán Prieto AM, van Schaik W, Rogers MRC, Coque TM, Baquero F, Corander J, Willems RJ. Global emergence and dissemination of enterococci as nosocomial pathogens: attack of the clones? *Front Microbiol*. 2016;7:788.
- Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. *Virulence*. 2012;3:421–33.
- Kristich CJ, Rice LB, Arias CA. Enterococcal infection – treatment and antibiotic resistance. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. *Enterococci: from commensals to leading causes of drug resistant infection*. Boston: Massachusetts; 2014.
- Lopardo H, Blanco MA. Métodos para detectar enterococos productores de β -lactamasa (Imágenes microbiológicas). *Rev Argent Microbiol*. 2007;39:105.

18. Mainardi JL, Gutmann L, Acar JF, Goldstein FW. Synergistic effect of amoxicillin and cefotaxime against *Enterococcus faecalis*. *Antimicrob Agents Chemother*. 1995;39:1984–7.
19. Mainardi JL, Legrand R, Arthur M, Schoot B, Van Heijenoort, Gutmann L. Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in *Enterococcus faecium*. *J Biol Chem*. 2000;275:16490–6.
20. Metzidie E, Manolis EN, Pournaras S, Sofianou D, Tsakris A. Spread of an unusual penicillin and imipenem resistant but ampicillin-susceptible phenotype among *Enterococcus faecalis* clinical isolates. *J Antimicrob Chemother*. 2006;57:158–60.
21. Miró JM, Cervera C, García de la María C, Del Río A, Armero Y, Mestres CA. Success of ampicillin plus ceftriaxone rescue therapy for a relapse of *Enterococcus faecalis* native-valve endocarditis and *in vitro* data on double beta-lactam activity. *Scand J Infect Dis*. 2008;40:968–72.
22. Murray BE. The life and times of the *Enterococcus*. *Clin Microbiol Rev*. 1990;3:46–65.
23. Murray BE, Singh KV, Markowitz SM, Lopardo HA, Patterson JE, Zervos MJ, Rubeglio E, Eliopoulos GM, Rice LB, Goldstein FW, Jenkins SG, Caputo GM, Nasnas R, Moore LS, Wong ES, Weinstock G. Evidence for clonal spread of a single strain of beta-lactamase-producing *Enterococcus (Streptococcus) faecalis* to six hospitals in five states. *J Infect Dis*. 1991;163:780–5.
24. Murray BE, Lopardo H, Rubeglio E, Frosolono M, Singh K. Intrahospital spread of a single gentamicin-resistant beta-lactamase-producing strain of *Enterococcus faecalis* in Argentina. *Antimicrob Agents Chemother*. 1992;36:230–2.
25. Pietta E, Montealegre MC, Roh JH, Cocconcelli PS, Murray BE. *Enterococcus faecium* PBP5-S/R, the missing link between PBP5-S and PBP5-R. *Antimicrob Agents Chemother*. 2014;58:6978–81.
26. Predari SC, Gutierrez MA, Ribas C, Molinari GS, Santoianni JE. Susceptibility of *Enterococcus faecalis* to twelve antibiotics, time kill-assays, and high-level aminoglycoside resistance in a university hospital in Argentina. *Rev Argent Microbiol*. 1991;23:67–78.
27. Red Latinoamericana de Vigilancia de la Resistencia a los Antimicrobianos (ReLAVRA). Informe de Vigilancia de la Resistencia a los Antimicrobianos Argentina 2015; 2015. Disponible en: <http://antimicrobianos.com.ar/ATB/wp-content/uploads/2016/12/Informe-Resistencia-ARGENTINA-2015.pdf>
28. Sacco E, Cortes M, Josseaume N, Rice LB, Mainardi J-L, Arthur M. Serine/threonine protein phosphatase-mediated control of the peptidoglycan cross-linking L,D-transpeptidase pathway in *Enterococcus faecium*. *MBio*. 2014;5, <http://dx.doi.org/10.1128/mBio.01446-14>, e01446–e1514 [On-line].
29. Sarti M, Campanile F, Sabia C, Santagati M, Gargiulo R, Stefani S. Polyclonal diffusion of beta-lactamase-producing *Enterococcus faecium*. *J Clin Microbiol*. 2012;50:169–72.
30. Shepard BD, Gilmore MS. Antibiotic-resistant enterococci: the mechanisms and dynamics of drug introduction and resistance. *Microbes Infect*. 2002;4:215–24.